All posts by medical

Cell Biology

Hamilton Thorne to Present at the H.C. Wainwright 22nd Annual Global Investment Conference – GlobeNewswire

BEVERLY, Mass. and TORONTO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that David Wolf, President and CEO of Hamilton Thorne Ltd., will deliver a virtual presentation at the upcomingH.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 2:30 pm EDT. Mr. Wolf will also be available for virtual one-on-one meetings during the conference.

About Hamilton Thorne Ltd. (www.hamiltonthorne.ltd)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thornes customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Here is the original post:
Hamilton Thorne to Present at the H.C. Wainwright 22nd Annual Global Investment Conference - GlobeNewswire

Cell Biology

New additions adding to site’s business mix – The Chatham News + Record

BY LARS DOLDER

News + Record Correspondent

The Plant promises to be the pinnacle of Pittsboro-produced potations, so libation lovers will be pleased to welcome two new additions to the Chatham Beverage District.

Vortex Roasters

Mark and Dawn Stover had just opened for business when Gov. Roy Cooper enacted pandemic restrictions.

Well always remember when we started business, Mark Stover said. We literally incorporated and signed our lease 10 days before the shelter-in-place order.

Stover feared the couples fledgling coffee business might suffer under the abnormal conditions, but he was surprised to discover unique advantages to their position.

It kind of worried us a little bit, he said, but the one thing that was actually good is that we had already planned, as a new business, to operate on a pretty slim budget initially. When everything shut down it put a lot of people that were actually very well-established back to where we were.

Not having established business practices allowed Vortex Roasters to pivot without sustaining significant revenue loss. From the beginning it was obvious online sales would determine the companys success.

We really pushed the online side of things and thats where our business grew very well in the past two to three months, Stover said.

Business has not been without its challenges, though. Global shipping delays have made it difficult to maintain a consistent supply of beans.

Systemic issues of importation and customs navigation will indurate the bean shortage, Stover suspects. Prices, in turn, will climb. Look out, he said, for some of your favorite beans to become a rare commodity.

We may see certain beans being unable to be obtained or have a much lower volume imported in the United States, he said.

BMC Brewing

John and Carmen Rice are The Plants newest business owners. Their brewery is set to open in early 2021. The brewerys name is, of course, an initialism, but to learn its meaning inquisitors must visit the taproom in person, John Rice said.

Rice made his career as a pharmaceutical researcher specializing in drug discovery, cell biology and yeast physiology, but his foray into commercial brewing has been decades in the making.

This will be my first venture into the business of brewing, Rice said, but Ive been a home brewer for three decades.

He has watched the craft beer scene develop from a niche interest into a sweeping trend.

Back in the late 90s, Rice said, we were thinking, 10 microbreweries? Theres no more room for any more microbreweries. Now there are more than 300 microbreweries in North Carolina. So, you know, I was wrong there seems to be plenty of room.

After years of deliberation, Rice decided in 2019 that it was finally time to ditch his career in research and pursue his lifelong passion. Then the coronavirus pandemic broke out.

With the pandemic, things have slowed down, Rice said. Beer sales are down across the state and some of the small microbreweries are struggling. Well wait and see what happens. We wont be open until next year and hopefully by then well have a vaccine and things will start picking up again.

After pandemic fears have abated and lingering restrictions have been lifted, the local beer industry will emerge stronger than ever, Rice said. He expects microbreweries to continue their subversion of the industrys major players.

It seems like the business is going toward a more local approach where a local taproom is a good viable business but the bigger breweries, particularly the well-known Miller, Budweiser and all of them are only growing through acquisition, Rice said.

Rice is eager to capitalize on the fertile market before it saturates, and he thinks Pittsboro is the perfect place to do it.

Local seems more of a solution than trying to prod into downtown Raleigh, Rice said. We like the idea of just being local, supporting Pittsboro, and Pittsboro supporting us.

Learn more about what's going on at The Plant now by clicking here.

See more here:
New additions adding to site's business mix - The Chatham News + Record

Cell Biology

Berkeley Lights to Participate in the Morgan Stanley 2020 Healthcare Conference – BioSpace

EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

Berkeley Lights management is scheduled for a fireside chat on Tuesday, September 15 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the Investors section of the company website at: http://www.berkeleylights.com.

About Berkeley Lights

Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

Berkeley Lights Beacon and Lightning systems and Culture Station instrument are: FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Press Contactberkeleylights@bulleitgroup.com

Investor Contactir@berkeleylights.com

More:
Berkeley Lights to Participate in the Morgan Stanley 2020 Healthcare Conference - BioSpace

Cell Biology

COVID-19 Testing Labs Can Skip RNA Extraction, Simplifying and Accelerating Workflow, With New Promega XpressAmp Direct Amplification Reagents -…

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200902005210/en/

COVID-19 testing labs can use Promega XpressAmp Direct Amplification Reagents for RNA extraction-free sample preparation that is simple and automation-friendly. (Graphic: Business Wire)

The simple, direct amplification workflow involves:

Promega, a global manufacturer of reagents, assays and benchtop instruments essential for COVID-19 research, drug development and diagnostic testing, including RNA extraction, increased production dramatically since the start of the pandemic to address a 10-fold increase in demand. Reagent manufacturers worldwide responded similarly. Still, supply and demand gaps remain, particularly around RNA extraction. Promega sought a solution that leverages the companys more than 40 years of experience in both sample preparation and amplification, especially its work with challenging samples such as forensic crime scene evidence. The result is a direct amplification method that simplifies and accelerates time to qPCR results.

We are constantly exploring ways to apply our scientific and manufacturing expertise to help labs address the unprecedented demands they are facing for COVID-19 testing, says Promega Chief Medical Officer Ashley Anderson. Offering an option to skip RNA extraction and move directly to PCR amplification not only saves time, it also addresses potential supply constraints since the many buffers and optimization reagents needed for extraction and wash steps in a typical PCR workflow are no longer needed.

XpressAmp Direct Amplification Reagents are a custom product that can be adjusted in numerous ways to suit a laboratorys specific needs. Options include purchasing in bulk, changing the dispense size or reformatting and relabeling.

Direct amplification technology continues Promega Corporations support of the worldwide fight against COVID-19.

Promega tools used for COVID-19 applications are a small subset of the 4,000 products Promega manufactures and distributes globally, serving research, pharma, clinical, forensic and applied markets. These tools are used for a myriad of applications in human health, disease, genetic identity, drug development, clinical diagnostics and more.

To learn more about Promega XpressAmp Direct Amplification Reagents, visit http://www.promega.com/PromegaXpressAmp

About Promega Corporation

Promega Corporation is a leader in providing innovative solutions andtechnical supportto the life sciences industry. The companys product portfolio of over 4,000 products support a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. For over 40 years these tools and technologies have grown in their application and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information, visit http://www.promega.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005210/en/

View post:
COVID-19 Testing Labs Can Skip RNA Extraction, Simplifying and Accelerating Workflow, With New Promega XpressAmp Direct Amplification Reagents -...

Cell Biology

Biological Microscope Objectives Market Current Trends, Business Strategies and Industry Overview 2020 to 2025 – Bulletin Line

Meridian Market Consultants (MMC) has published a new report titled, 2020-2025 Global and Regional Biological Microscope Objectives Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report (Enhanced Version).According to the report,Global Biological Microscope Objectives Market, is expected to grow at a significant CAGR for the period between 2020 and 2025.

Get Exclusive Sample Copy of the Report@ https://meridianmarketconsultants.com/requst?rid=%20111230647

As per the report,the microscopes are plugging away in numerous fields with its potential to enlarge and glorify the representation of an object that cannot be observed through bare eyes, thereby the global biological microscope objective market is witnessing a satisfactory growth these days. Fundamentally, a kind of microscope which promotes its utility in order to examine tissues, cells, and other biological specimens, is known as a biological microscope.

Furthermore, one of the most important constituents of an optical microscope is a microscope objective as it forms the primary image and is solely responsible for the quality of the image that the microscope is going to produce. In addition to that, the microscope objective is helpful in enlarging or glorifying a specific biological sample so that each and every fine detail of the sample can be observed.

Notably, the name of the microscope objectives is derived from the fact that they are the only component that is closest to the specimen that is being imaged. As a matter of fact, the researchers are always in constant requirement for new and advanced objective lenses to examine unique kinds of substances, cells and other objects as closely as possible. Owing to which, the technological advancements intended at bringing novelty in objective lenses have been very common in the present times. Attributing to such factors, the global biological microscope objectives market is expected to flourish positively in the near future.

Ask for [emailprotected]https://meridianmarketconsultants.com/ask-for-customization?rid=%20111230647

In the similar manner, the comprehensive demand of the biological microscopes is also projected to quicken the growth of the global biological microscope objectives market in the forthcoming future as it serves its application in semiconductor, material science, pharmaceutical, life science, and biotechnology industries.

More essentially, the microscope objectives assist in blood microscopy, cell biology research, immunohistochemistry in cancer research, sputum microscopy, urine analysis, and many more, thus the field of life sciences observe high demand of biological microscopes, in turn supporting the growth of the global biological microscope objectives market.

Along with that, several key market players are aiming their attention at product integration with the automated platforms in order to grow their applications in the field of material as well as life sciences.

Remarkably, the wide usage of microscope objectives potentially boosts its operational efficiency in different applications including manufacturing units and hospitals. Hence, the global biological microscope objectives market is projected to augment rapidly in the coming years.

Ask Industry Expert @https://meridianmarketconsultants.com/ask-analyst?rid=%20111230647

MMC study identifies some of the key participating players in the biological microscope objectives market globally are ZEISS International, Olympus Corporation, Nikon Instruments Inc., Leica Microsystems, Meiji Techno, and Newport Corporation, among several others.

About Meridian Market Consultants:

Meridian Market Consultants (MMC) is committed to provide deep insights that serve as a creative tool for the client that enables it to perform confidently in the market. At MMC we adhere to the clients needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Meridian Market Consultants (MMC)

1321, Louetta Road,

#440, Cypress, Texas, 77429

United States

Tel: +1-(281)-619-8646

For Sales Query:[emailprotected]

Find Us on Linkedin: https://www.linkedin.com/company/meridian-market-consultants

Here is the original post:
Biological Microscope Objectives Market Current Trends, Business Strategies and Industry Overview 2020 to 2025 - Bulletin Line

Cell Biology

The Drug Supply Chain Is Broken. A New Breakthrough Paves The Way For On-Demand Plant-Based Medicines – Forbes

When Covid hit and hospitals started reporting drug shortages, it became clear that our drug supply ... [+] chain was broken. In a Nature paper, Christina Smolke reports a breakthrough in making plant-based medicines that lays the foundation for a flexible, on-demand drug supply chain. Photo by The Tonik on Unsplash

When Covid hit and hospitals started reporting shortages of hydroxychloroquine and other medicines vital to patients with conditions like malaria, lupus, asthma, and COPD, it became clear that our drug supply chain was broken.

Nearly all plant-based medicines including hydroxychloroquine are made outside the US because the medicinal plants used to make them grow in very particular climates. For example, India manufactures 70% of the world's supply of hydroxychloroquine. (India initially banned the drugs export to the US but later reversed its decision after President Trump threatened retaliation.)

Plant-based drugs have long been subjected to production limitations and medical shortages. Environmental disasters like the Australian wildfires or sudden spikes in the demand (similar to what the US experienced at the onset of the pandemic) can result in patients lacking desperately needed medicines.

Were experiencing a number of challenges with supply chains for pharmaceuticals today, especially in supply chains that are based upon farming, says Stanford professor Christina Smolke.

In a Nature paper published today, Smolke and her lab report a breakthrough in making plant-based medicines that lays the foundation for a flexible, on-demand drug supply chain to replace our current fragmented and slow-moving one. The solution: use yeast instead of plants.

Using the tools of synthetic biology, which combines advances in our ability to edit DNA with computation and automation, Smolkes lab successfully added the genes from plants into bakers yeast that make drugs called tropane alkaloids. This class of drugs includes hyoscyamine and scopolamine, two traditional drugs used to treat neuromuscular disorders like Parkinson's as well as nausea from motion sickness and surgery.

Stanford professor Christina Smolke

Smolkes lab had previously demonstrated a similar ability to engineer yeast to ferment opioids, another plant-based class of medicines. That process added over twenty genes from five different organisms to yeast cells, resulting in the first narcotic produced using synthetic biology. But the project reported today was far more challenging and has bigger implications for the way we make plant-based medicines.

The way that plants have evolved to make tropane alkaloids is through a very complicated biosynthesis scheme, says Smolke. In nature, the pathway depends on enzymes that only work in specific tissues, cell types, and organelles within the plant.

Smolkes team took what it calls a whole-cell engineering approach to the problem. It not only rebuilt the pathways 26 different enzymes and proteins in yeast, but it also recreated the cellular microfactories needed for the pathway to work as it would in plants. This included special transporter enzymes that shuttle the intermediate chemical into and out of the various microfactories as needed during biosynthesis of the chemical. Replicating these various cellular processes in a single microorganism like yeast has never been done.

The result: the same basic yeast that makes bread and wine can now also ferment some of the most complex molecules known to humankind.

The research is a strong indicator that the vast majority of plant-based drugs can be produced through industrial fermentation in the coming years. Rather than the months or years it takes to grow, harvest, and extract key molecules from medicinal plants, a fermentation-based manufacturing approach can be implemented in any location and takes just days to produce target compounds, enabling the production of essential medicines when and where theyre needed.

Smolkes research also sets the stage for others to discover improved drugs starting from the original. By making thousands of individual changes to the original biosynthetic pathway, scientists can discover new tropane alkaloid derivatives with new properties, which could be useful as new therapeutics for CNS disorders.

This type of work lays the foundation for being able to develop a bio-based fermentation process for producing these and related molecules, says Smolke.

In 2013, Smolke founded Antheia, a biotech startup that is bringing to market next-generation plant-inspired medicines like these. Antheia developed a fermentation process that takes the work from the lab to commercial scales. These days, Smolke spends most of her time at Antheia, turning her labs research into commercial products.

I think it's a very unique opportunity as an engineer to have a hand in both innovating the breakthrough research that underlies these innovations and then guiding them to commercialization, Smolke says. There's a lot of steps beyond what we would do in an academic lab to actually bring something to the stage where it can have a real impact in the world.

Follow me on Twitter at @johncumbers and @synbiobeta. Subscribe to my weekly newsletters in synthetic biology. Thank you to Kevin Costa for additional research and reporting in this article. Im the founder of SynBioBeta, and some of the companies that I write about are sponsors of the SynBioBeta conference and weekly digest. Heres the full list of SynBioBeta sponsors.

See the original post here:
The Drug Supply Chain Is Broken. A New Breakthrough Paves The Way For On-Demand Plant-Based Medicines - Forbes

Immunology

Insights on the Human Microbiome Immunology Therapeutics Global Market to 2025 – Featuring Finch Therapeutics, MaaT Pharma & Merck Among Others -…

Dublin, Sept. 02, 2020 (GLOBE NEWSWIRE) -- The "Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025" clinical trials has been added to ResearchAndMarkets.com's offering.

The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology. The relevance that it has shown for the welfare of the society and pharmaceutical industry has led to the development of a transdisciplinary environment that is however conducive to innovation with a mission to abolish the limitations in the pharmaceutical industry through excellence in microbiome research, awareness and outreach. Over the years now, gut microbiome is estimated to implicate success for the various immunotherapies.

Microbiome's role in immunology practices is to transform world-class treatment into the medicine of today and tomorrow. It is highly recognizable that the healthcare issues that mankind is facing today is now bigger than any one solution. The treatment of certain diseases requires multiple options for the treatment and ultimately prevention. Therefore, the amalgamation of two different treatment paradigms i.e. microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time. The ways in which microbiome is understood and manipulated to serve the immunological aspects has given great interest to all the researchers.

The essential and usual concept of immunology depicts targeting the immune system of the body to provoke an immune response with huge impact but then the unsuccessful implication of immunology therapies driven treatments led to an exploration of several other basic concepts that could play an important role in boosting the immune system when combined. Looking forward, the microbiome community in the gut represented beneficial patterns with respect to further research. The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.

All over the world, the amalgamation of the two has been well accepted and appreciated by the patients, physicians and the clinicians. Investigation of all the working sides of microbiome and how it plays an important role in boosting the manipulated immune cells have recently started in large numbers as the technology available in the medical field allows to capture it accurately. To facilitate the microbiome and immunology community in order to extract the best and trending opportunities that are stemmed into the microbiome research, the experts from both the relevant disciplines are analyzing it through clinical researches and surveys. Further, the area is getting supported by 86 different clinical trials getting conducted in different countries.

The Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025 report summarizes the view of the wider opportunities that are associated microbiome community for the advancement of the scientific information regarding immunology. The science that is related to microbiome has high interdisciplinary and various opportunities that somehow have remained hidden in the medical world. It is believed that the opportunities and all the desirable tangible benefits microbiome is capable of delivering when combined with immunology is large and needs coordinated and constructive approach. The call to the two different sectors i.e. microbiology and immunology is estimated to unlock the potential and promising benefits of microbiome. The approach leading to the extraction of advantages if properly embedded in the microbiome and immunology research, the future benefits will be huge

Report Highlights:

Key Topics Covered:

1. Overview of Microbiome1.1 Introduction to Microbiome1.2 History & Evolution of Microbiome

2. Role of Microbiome in Human Body

3. Microbiome: Various Forms3.1 Gut Microbiome3.2 Lung Microbiome3.3 Skin Microbiome3.4 Microbiome in Other Parts of the Body

4. Mechanism of Microbiome Activity4.1 Nature of Immune Response4.1.1 Immunosuppressive Activity4.1.2 Immunostimulatory Activity4.2 Messengers Involves in Microbiome Mechanism4.2.1 MAMPs/PAMPs4.2.2 Microbial Metabolites As Messengers4.2.3 Host Cytokines As Messengers4.2.4 Immune Cells As Messengers

5. Technological Requirement for Microbiota5.1 Technologies Used5.1.1 iChip5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME)5.1.3 Gut-on-a-Chip System5.1.4 Colonic Stem Cell Construction5.2 Harnessing & Engineering the Microbiome5.2.1 Additive Approaches5.2.2 Subtractive Approaches

6. Need for Microbiome Immunology

7. Therapeutic Applications of Microbiome Immunology7.1 Microbiome Therapy7.2 Precision Medicine7.3 Drug discovery7.4 Biomarkers & Therapy Optimization

8. Human Microbiota in Infectious Diseases8.1 Infection with Clostridium Difficile8.2 Infection with Helicobacter Pylori8.3 Bacterial Vaginosis8.4 Infection with HIV

9. The Human Microbiota & Liver Diseases9.1 Non-Alcoholic Fatty Liver Disease (NAFLD)9.2 Alcoholic Liver Diseases (ALD)9.3 Liver Fibrosis & Cirrhosis

10. The Human Microbiota & Metabolic Disorders10.1 Obesity10.2 Type 2 Diabetes

11. The Human Microbiota & Other Diseases11.1 Microbiota & Allergic Diseases11.2 Microbiota & Psychiatric Diseases

12. Microbiome in Immuno Oncology12.1 Role of Microbiome in Immuno Oncology12.2 Microbiome Mechanism in Oncogenesis & Tumor Suppression

13. Microbiome Application by Cancer Types13.1 Gastric Cancer13.2 Colorectal Cancer13.3 Esophageal Cancer13.4 Hepatocellular Carcinoma13.5 Melanoma13.6 Solid Tumors

14. Industrial Approaches of Microbiome Therapy in Oncology14.1 Bacterial Approaches14.1.1 Fecal Microbiota Transplantation (FMT)14.1.2 Synthetic Bacteria14.1.3 Microbial Culture14.2 Microbiome as Vaccine14.3 Microbiome as Small Molecules14.4 Microbiome Therapy using Phage Virus

15. Global Human Microbiome Market Analysis15.1 Overview15.2 Human Microbiome Market Segmentation15.2.1 Regional Segmentation15.2.2 Disease Based Segmentation15.2.3 Segmentation by Application

16. Clinical Pipeline of Microbiome Based Therapy16.1 Microbiome Modulators in Clinical Trial16.2 Cancer Related Clinical Trials16.2.1 Preclinical & Discovery Phase16.2.2 Active Clinical Trials16.3 Clinical Trial Related To FMT16.3.1 Clinical Trial for Recurrent C. difficile16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD)16.3.3 Other FMT Related Clinical Trials

17. Global Microbiome Modulators Clinical Pipeline By Company, Indication & Phase17.1 Research17.2 Preclinical17.3 Clinical17.4 Phase-I17.5 Phase-I/II17.6 Phase-II17.7 Phase-II/III17.8 Phase-III

18. Marketed Microbiome Modulators Clinical Insight18.1 Sodium Oligomannurarate - Shanghai Green Valley Pharmaceutical18.2 Miya-BM

19. Global Microbiome Immunology Therapeutics Market Growth Drivers

20. Microbiome Technology - Investments, Acquisitions & Collaborations by Leading Microbiome Companies

21. Blockades in the Microbiome Immunology Market21.1 Stable Engraftment21.2 Development of Clinically Relevant Sensors21.3 Robustness and Evolutionary Stability of Genetic Circuits21.4 Regulation, Safety and Biocontainment

22. Global Microbiome Immunology Market Future Panorama

23. Competitive Landscape23.1 4D Pharma23.2 AbbVie23.3 AstraZeneca plc23.4 Biocodex23.5 Bristol Mayer Squibb23.6 Corebiome/Diversigen23.7 Elogi Bioscience23.8 Enterome23.9 Ferring Pharmaceuticals23.10 Finch Therapeutics23.11 Maat Pharma23.12 Merck23.13 Microbiome Therapeutics23.14 Novartis23.15 OpenBiome23.16 Pfizer23.17 Rebiotix23.18 Second Genome23.19 Seres Therapeutics23.20 Symberix23.21 Takeda Pharmaceuticals23.22 Vedanta Bioscience

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/d6z6gb

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See original here:
Insights on the Human Microbiome Immunology Therapeutics Global Market to 2025 - Featuring Finch Therapeutics, MaaT Pharma & Merck Among Others -...

Immunology

Immunologists Receive Multi-Million Funding Boost to Research Role of Immune System in COVID-19 – HospiMedica

Immunologists from The University of Edinburgh (Edinburgh, Scotland) have received a multimillion pound funding boost to research the role of the immune system in COVID-19.

The funding comes from the UK Coronavirus Immunology Consortium (UK-CIC), a major initiative set-up to tackle the COVID-19 pandemic. The GBP 8.4 million Consortium launched by UK Research and Innovation and the National Institute for Health Research brings together 17 UK research institutes to investigate vital aspects of disease immunity, including why the disease affects some people worse than others.

Dr. Kenneth Baillie, from the Roslin Institute, will work with collaborators to analyze immunity data in people hospitalized because of COVID-19 symptoms. Professor Sarah Walmsley from the Centre for Inflammation Research will research the role of immune systems in determining susceptibility to the virus and how it varies as people age. A third study led by Dr. Christopher Lucas from the Centre for Inflammation Research will investigate the key features of fatal COVID-19 cases and the impact the virus has on lungs and other vital organs. UK-CIC will use resources from ongoing UK studies, including ISARIC-4C, which is following more than 75,000 people hospitalized with COVID-19, and GenOMICC, a study to sequence the genomes of people with the disease, led by Dr. Kenneth Baillie.

We have learned so much from COVID-19 patients during the past six months. However, there is only so much that we can learn from clinical examinations and blood tests, said Dr. Christopher Lucas. By having a deeper look at those who have died from COVID-19 through post-mortem examination, we will increase our understanding of what is happening to the body in the most severe cases of this disease. Critically, this will allow us to rapidly answer key clinical questions and help inform the care of patients and the development of new treatments.

Related Links:The University of Edinburgh

The rest is here:
Immunologists Receive Multi-Million Funding Boost to Research Role of Immune System in COVID-19 - HospiMedica

Immunology

UK government to invest 8.4 million into COVID-19 immunology research – Drug Target Review

The UK government will invest 8.4 million in COVID-19 research projects to reveal more information that can be used to develop therapies and vaccines against the disease.

The UK government has announced it is investing 8.4 million in COVID-19 immunology research projects across the UK, including at the Universities of Edinburgh, Glasgow and Dundee. According to the government, this is the biggest ever contribution to COVID-19 immunology research in the UK.

Three new UK-wide studies will receive funding from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR) to understand immune responses to COVID-19.It is hoped these studies will improve the treatment of patients and inform the development of vaccines and therapies.

The Scottish universities are taking part in the largest study, the UK Coronavirus Immunology Consortium, which will receive 6.5 million and bring together leading immunologists from 17 UK universities. The University of Edinburgh is also involved in another study.

Dr Christopher Lucas at the University of Edinburgh, will lead a study on the key features of fatal COVID-19 and the impact the virus has upon the lungs and other vital organs. Using authorised hospital post-mortem examinations of patients who have died from COVID-19, this study will provide a unique opportunity for expert clinicians and scientists to study the whole body in a level of detail that is not possible during life.

We have learned so much from COVID-19 patients during the past six months. However, there is only so much that we can learn from clinical examinations and blood tests.By having a deeper look at those who have died from COVID-19 through post-mortem examination, we will increase our understanding of what is happening to the body in the most severe cases of this disease.Critically, this will allow us to rapidly answer key clinical questions and help inform the care of patients and the development of new treatments, Dr Lucas said.

The UK Coronavirus Immunology Consortium will investigate key questions including how long immunity from COVID-19 lasts andwhy some patients immune systems are better able to fight off the virus.

According to the researchers, better understanding of these immune responses, particularly the T-cell response, could provide targets for new therapies to treat COVID-19 and inform the efforts to develop a vaccine.

The project will use samples and data from major UK COVID-19 projects already underway, funded by UKRI and NIHR.

Professor Massimo Palmarini, Director of the Medical Research Council-University of Glasgow Centre for Virus Research (CVR) said: My colleagues and I at the CVR are extremely proud to be involved in the UK-CIC consortium and are grateful to UKRI and NIHR for the generous funding support. It is now more important than ever that the immunology community work together, as we aim to address important, unanswered questions about SARS-CoV-2 as we move through this pandemic.

Read the original post:
UK government to invest 8.4 million into COVID-19 immunology research - Drug Target Review

Immunology

Trinity is at the Heart of Immunology. It Needs to Take a Lead on Testing – The University Times

" );jQuery( ".stuck" ).fadeIn( 300 );}},{offset: '0%',});if ($(window).width() -1 || ref1.indexOf(twitter) > -1 || ref1.indexOf(tco) > -1 ) {jQuery('.utpost-content').readmore({ speed: 75, moreLink: '', lessLink: '', collapsedHeight: 375, embedCSS: false, heightMargin: 100, });} else { }}});}); jQuery(window).resize(function() {console.log(jQuery(window).width());if (jQuery(window).width() > 584) { jQuery('.utpost-content').readmore('destroy'); }else{ }});jQuery(window).trigger('resize');

In an interview with The University Times earlier this week, Trinity immunologist Luke ONeill advised that College test all staff and students for the coronavirus twice weekly. A familiar and reassuring voice throughout the pandemic, ONeill asserted that frequent testing was the best way to minimise the chances of outbreaks on campus.

Of course, it is not exactly new information that frequent testing is the best way to contain the virus and ensure that transmission is minimised, especially given the asymptomatic aspect of the disease.

College has already taken steps to ensure that staff and students have access to testing facilities such as the on-site coronavirus testing facilities set to open before the beginning of first term and isolation rooms being provided in Trinitys buildings for staff and students who develop coronavirus symptoms on campus.

David McGrath, director of the College Health Service, told this paper that the testing facilities would as far as possible reduce the development of clusters within the College particularly within student accommodation.

However, these on-campus test facilities will only be used to test students who have displayed symptoms. Students who are asymptomatic could unknowingly be passing on the virus. As McGrath said, students have a responsibility not to infect the public, but they cant take precautions if they dont know whether they are infected.

A Science Foundation Ireland report launched last week revealed that Ireland ranked number one worldwide for immunology research in 2019. With Trinity considered the centre of immunology research in Ireland, College has no shortage of expert advice to consult and take guidance from when it comes to drawing up a testing and containment strategy for campus next year.

Trinity put public safety first when they made the decision to close before other universities when the coronavirus started to take hold in Ireland last March. An on-campus test site and isolation facilities are great first steps in ensuring that campus can reopen safely. However, if College wants to continue to lead the way in university health guidelines, then there needs to be further consideration of testing for all staff and students, not just those with symptoms.

Go here to read the rest:
Trinity is at the Heart of Immunology. It Needs to Take a Lead on Testing - The University Times